Analysts Set CG Oncology, Inc. (NASDAQ:CGON) Price Target at $63.88

CG Oncology, Inc. (NASDAQ:CGON) has been given an average recommendation of “Buy” by the nine analysts that are currently covering the stock, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $63.88.

A number of research firms recently weighed in on CGON. Roth Mkm started coverage on CG Oncology in a research note on Tuesday, August 27th. They issued a “buy” rating and a $65.00 price target on the stock. UBS Group began coverage on shares of CG Oncology in a research report on Thursday, October 24th. They set a “buy” rating and a $60.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $75.00 price objective on shares of CG Oncology in a research note on Tuesday. Royal Bank of Canada initiated coverage on shares of CG Oncology in a research report on Monday, September 23rd. They set an “outperform” rating and a $66.00 target price on the stock. Finally, Roth Capital upgraded shares of CG Oncology to a “strong-buy” rating in a research report on Tuesday, August 27th.

CG Oncology Stock Down 6.8 %

CG Oncology stock opened at $36.98 on Friday. The stock has a 50 day moving average of $36.87 and a two-hundred day moving average of $34.80. CG Oncology has a twelve month low of $25.77 and a twelve month high of $50.23.

Insider Transactions at CG Oncology

In related news, Director Hong Fang Song sold 650,455 shares of the company’s stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $35.36, for a total value of $23,000,088.80. Following the sale, the director now owns 586,982 shares of the company’s stock, valued at approximately $20,755,683.52. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets acquired a new position in shares of CG Oncology in the first quarter valued at approximately $492,000. Vanguard Group Inc. purchased a new position in shares of CG Oncology during the 1st quarter worth $97,678,000. Ameritas Investment Partners Inc. acquired a new stake in shares of CG Oncology during the first quarter worth $102,000. American International Group Inc. purchased a new stake in shares of CG Oncology in the first quarter valued at $13,443,000. Finally, Decheng Capital LLC purchased a new stake in shares of CG Oncology in the first quarter valued at $239,642,000. 26.56% of the stock is currently owned by hedge funds and other institutional investors.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.